Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q3 2024 · 10-Q
Revenue$0.00$0.00no prior Q3 2023 on file Net Income-$82.09M-$82.09MN/M vs Q3 2023 EPS Diluted-$0.31-$0.31N/M vs Q3 2023 Operating Income-$67,876,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$86,329,000N/M ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end